Clinical trials: CtDNA
Colorectal Neoplasms
Prospective Multicenter Cohort Study of Clinical and Molecular Biomarkers in Colorectal Cancer
This prospective, multicenter observational study aims to identify clinical and molecular biomarkers associated with treatment response, disease recurrence, progression, and survival in patients with colorectal cancer (CRC).
- Trial name
- NCT07913802
- Where
- 4 sites in Austria
- Volunteers
- 200 people
- Sponsor
- Vorarlberg Institute for Vascular Investigation and Treatment
Peripheral T Cell Lymphoma
Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas
The purpose of this study is to assess the feasibility of analyzing circulating tumor DNA (ctDNA) as a biomarker using the shallow whole genome sequencing (lpWGS) technique coupled with deep sequencing of a targeted panel of…
- Trial name
- PTCL-SEQ (NCT06089941)
- Testing
- circulating tumoral DNA detection
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre Henri Becquerel
Breast Cancer, Non Small Cell Lung Cancer
Minimal Residual Disease in Solid Malignancies
The IMRD study is a single-centre, prospective observational study which will investigate the rate of ctDNA (circulating tumor DNA) detection from the start of adjuvant therapy following curative-intent surgery.
- Conditions
- Breast Cancer, Non Small Cell Lung Cancer, Prostate Cancer, High Grade Serous Ovarian Cancer
- Trial name
- IMRD (NCT07268469)
- Testing
- ctDNA detection
- Volunteers
- 840 people
- Sponsor
- European Institute of Oncology
Cancer, Lung, Cancer, Breast
Early Detection of Five Common Cancers Using the ctDNA Analysing Test
This is a multi-centre, prospective cohort study, aiming to evaluate a blood test in early detection of the four common cancers, based on the investigation of the circulating tumour DNA (ctDNA).
- Conditions
- Cancer, Lung, Cancer, Breast, Cancer Liver, Cancer, Colorectal
- Trial name
- K-DETEK (NCT05227261)
- Where
- Vietnam
- Volunteers
- 9,057 people, healthy volunteers welcome
- Sponsor
- Gene Solutions
BRAF V600 Colorectal Cancer
Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
The goal of this clinical trial is to learn if Iparomlimab and Tuvonralimab combined with bevacizumab and FOLFIRI (IB-FOLFIRI) is safe and effective in treating adults with BRAF V600E-mutant metastatic colorectal cancer (mCRC).
- Trial name
- NCT07150247
- Testing
- Iparomlimab and Tuvonralimab, Bevacizumab, 5-Fluorouracil
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-sen University
Liver Metastases
ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases
To determine if the detection of ctDNA after surgical resection of CLM can stratify patients into high and low-risk cohorts for early disease recurrence in order to inform post-operative adjuvant therapy.
- Trial name
- NCT05062317
- Testing
- Leucovorin, 5-FLUOROURACIL, Oxaliplatin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- M.D. Anderson Cancer Center
Diffuse Large B Cell Lymphoma
Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance
Patients suffering from diffuse large B-cell lymphoma (DLBCL) who relapse within 12 months of chemotherapy usually undergo salvage therapies, followed by autologous transplant with a low success rate.
- Trial name
- NCT03311958
- Testing
- Nivolumab, IV, 240 mg
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Fox Chase Cancer Center
Colorectal Neoplasms
Presence of Circulating Tumor DNA in Colorectal Cancer
Cancer is a DNA disease characterized by the presence of genetics alterations in cancer cells. The recent studies underline that these recurring alterations must be considered as a good molecular marker.
- Trial name
- ALGECOLS (NCT01198743)
- Where
- France
- Volunteers
- 261 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Cancer
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
This trial is a multicenter, open-label, non-comparative, phase II, biomarker-driven adjuvant treatment study involving the periodic collection and analysis of blood samples from patients with HR-positive/HER2-negative…
- Trial name
- MiRaDoR (NCT05708235)
- Testing
- Giredestrant, Abemaciclib, Inavolisib
- Where
- 41 sites in Spain, United Kingdom
- Volunteers
- 976 people
- Sponsor
- MedSIR
Cervical Cancer, Ovarian Clear Cell Carcinoma
Asian Multicenter Prospective Study of ctDNA Sequencing
This study is a genetic analysis of aberrations in circulating tumor DNA (ctDNA) in patients in Asian countries. This study protocol is divided into parts describing several subanalyses that differ in terms of cancer types…
- Conditions
- Cervical Cancer, Ovarian Clear Cell Carcinoma, Nasopharyngeal Carcinoma, Ovarian Cancer
- Trial name
- A-TRAIN (NCT05099978)
- Testing
- NGS analysis of ctDNA
- Where
- 19 sites in Japan, Malaysia and 6 more
- Volunteers
- 506 people
- Sponsor
- National Cancer Center, Japan
Metastatic Colorectal Cancer ctDNA Surveillance
Using ctDNA Methylation to Monitor Metastatic Colorectal Cancer Treatment (PROMET)
Multi-center observational clinical study to evaluate the application value of ctDNA methylation monitoring in efficacy assessment and relapse prediction in patients diagnosed with recurrence or metastatic colorectal cancer…
- Trial name
- NCT07283575
- Testing
- Plasma ctDNA methylation profiling
- Where
- China
- Volunteers
- 497 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
On-treatment Surveillance of Tumor Evolution and Response to Systemic Treatment in Bile Duct and Liver Cancer
The BILLIONSTARS study is a prospective, single arm observational study inviting patients diagnosed with hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCC) who are to be recommended locoregional intervention by surgery…
- Trial name
- BILLIONSTARS (NCT06877637)
- Where
- 3 sites in Sweden
- Volunteers
- 150 people
- Sponsor
- Region Skane
NSCLC, Chemoradiotherapy
Multi Dimensional Precise Exploration of Immunoconsolidation Therapy for Locally Advanced NSCLC After Chemo-radiotherapy
The purpose of this study is to carry out a prospective observational study in patients with locally advanced NSCLC receiving radical concurrent chemoradiotherapy and follow-up immune consolidation therapy.
- Conditions
- NSCLC, Chemoradiotherapy, ctDNA
- Trial name
- NSCLC (NCT04741633)
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Glioblastoma, Molecular Disease
Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.
Glioblastomas (GBM) are rare tumors of poor prognosis and their treatment is based on surgery followed by radiochemotherapy. Clinical and imaging evaluation is not always straightforward: the more or less complete surgery, the…
- Trial name
- Bi-GLAM (NCT03115138)
- Testing
- Correlation between molecular anomalies of the primary tumor and circulating tumor DNA
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Colon Cancer Stage II
Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation
The CIRCULATE study evaluates the adjuvant therapy in patients with colon cancer UICC stage II. The primary aim of the study is to compare the disease free survival in patients who are positive for postoperative circulating…
- Trial name
- CIRCULATE (NCT04089631)
- Testing
- Capecitabine
- Where
- Germany
- Volunteers
- 4,812 people
- Sponsor
- Technische Universität Dresden
Metastatic Invasive Lobular Carcinoma (mILC)
Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer
The goal of this study is to characterize early dynamic changes in ctDNA, which can aid in tailoring early therapy in patients with metastatic Invasive lobular carcinoma (ILC).
- Trial name
- LBC-Monitor (NCT06666439)
- Testing
- circulating tumor DNA (ctDNA)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Julia Foldi
Primary CNS Lymphoma
Diagnosis; Objective RespOnse; THErApy
Thi is a prospective and low-intervention clinical trial. We propose to design a panel of "core" genetic alterations by sequencing Cerebral Spinal Fluid (CSF) DNA in patients with confirmed or suspicious Primary Central Neurvous…
- Trial name
- DOROTHEA (NCT05036564)
- Testing
- Lumbar puncture
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- IRCCS San Raffaele
Gastric Cancer, Gastro-oesophageal Junction Cancer
Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Gastric Cancer
To explore the clinical value of dynamic detection of circulating tumor cells(CTCs), circulating tumor DNA(ctDNA) and cell-free DNA(cfDNA) in neoadjuvant chemotherapy and operation of resectable or locally advanced gastric or…
- Trial name
- NCT03957564
- Testing
- Neoadjuvant chemotherapy with PSOX regimen., Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in plasma., Detect the tumor related DNA in pathological tissues after operation.
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Affiliated Hospital of Qinghai University
Breast Cancer Stage IV
Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib
After an initial screening phase (SAFIR 03 - SCREENING) to identify patients with blood circulating mutated-PIK3CA tumours persistent, patients will be enrolled in the treatment phase of SAFIR 03 (SAFIR 03 - ARRIBA) that was…
- Trial name
- SAFIR 03 (NCT05625087)
- Testing
- Alpelisib, Ribociclib
- Where
- 44 sites in France
- Volunteers
- 4 people
- Sponsor
- UNICANCER
Metastatic Colorectal Cancer
ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer
The efficacy of combining TKI with PD-1 inhibitor in the treatment of advanced MSS/pMMR colorectal cancer with low levels of maxVAF in peripheral blood ctDNA failed with standard treatment was assessed, compared to standard…
- Trial name
- NCT06543836
- Testing
- Sintilimab, Fruquintinib or Regorafenib, Fruquintinib
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences